ImmunoPrecise Antibodies Ltd (IPA)

[Py11]

Functional, Human Antibodies Targeting SARS-CoV-2 Discovered Using IPA's Proprietary B cell Select™ and Single Step Cloning Hybridoma Technologies


https://www.newswire.ca/news-releases/functional-human-antibodies-targeting-sars-cov-2-discovered-using-ipa-s-proprietary-b-cell-select-tm-and-single-step-cloning-hybridoma-technologies-855898620.html

[ronpopeil]

Thank you so much!

[Py11]

https://www.talemtherapeutics.com/pipeline

They got into a research license agreement with Janssen (Johnson&Johnson) in April for an undisclosed target. Most likely for a type of cancer.

They recently announced several neutralizing SARS-cov-2 antibodies from their human and llama campaign. They will be soon announcing their antibodies discovered on Ligand’s (LGND) OmniAb platform (OmniRat) and also Rabbit antibodies. They’ll have 1600 Covid neutralizing mAbs.

In 2019 they created Talem Therapeutics which gives them the ability to out license their antibodies and partner with Big Pharma or whoever wants them. They already do business with several of big pharmas so the connections and trust are already there. When companies want to use IPAs services the audit process is roughly a year long so the Big Pharmas that are already on board should be very interested in their Covid discoveries.

They collaborated with the NIH for characterization of their antibodies. That should be released in a peer reviewed article in the near future. That will be big news and provide validation to the companies interested in licensing with them.

I don’t think there’s another company with the amount of sars-cov-2 specific antibodies like IPA. They did everything from the ground up and discovered mAbs from Humans, Llamas, Rabbits and OmniRat.

Will be interesting to see what moves they make this summer. They have potential to do several licensing deals (upfront payment+royalties) and also take an antibody cocktail through animal trials themselves.

IPA is also developing a saliva based test with the University of Victoria. A photographer from Bloomberg was there the other day so we should see some media coverage soon.

They also announced a Covid vaccine program that’s being funded by TRANSVAC in Europe. You only get that if your antibodies are good.

There’s so much going on with this company right now so we should be getting a lot of news soon. I’m sure their strategy is to bring in as many licensing deals (upfront payments) as possible which will set them up for future projects in immuno-oncology.

Few more developments and we should be headed to the Nasdaq where the real fun will start.

Nice to have another person on the board.

[ronpopeil]

Looks interesting. Any quick DD you can share? Seems undervalued. I see the covid programs. Any others? Nice platform

[Py11]

Hard to believe how undiscovered this still is. Great news released on Monday although
current investors expected that type of news so wasn’t much of a surprise. Results from Ligand platform should be out soon and I hope Ligand does a PR on IPAs discoveries using their platform. A lot of things happening with this company and I feel like we’ll have a big licensing deal happen this month.

[Py11]

IPA Confirms Discovery of Fully Human, Potent, Neutralizing Antibodies Targeting SARS-CoV-2

Source: PR Newswire (Canada)
IPA Announces Discovery of Functional Antibodies from Humans and Llama (VHH), Identified Using IPA Phage Display Technology

VICTORIA, BC, June 29, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV: IPA) (OTCQB: IPATF) (FSE: TQB2), an experienced leader in full-service, therapeutic antibody discovery and development, today announced the identification of numerous lead candidate antibodies with highly-potent neutralizing activity in vitro, which are being manufactured for further testing and possible inclusion in the Company's PolyTopeTM mAb Therapy to combat the COVID-19 pandemic.

ImmunoPrecise Antibodies Ltd. Logo (CNW Group/ImmunoPrecise Antibodies Ltd.)

On March 12th, 2020, ImmunoPrecise announced several preclinical programs currently being undertaken to assist in the efforts against SARS-CoV-2. Today's announcement updates the Company's progress on the development of a PolyTope™ mAb therapy designed to treat severely ill patients, as well as protect high-risk individuals such as those exposed to the virus, front-line workers, the elderly, and the immunocompromised.

ImmunoPrecise deployed several proprietary discovery platforms that leveraged the immune systems of humans, llama, rabbits and Ligand Pharmaceutical's (NASDAQ:LGND) OmniAbÒ genetically engineered rats producing human antibodies. The neutralizing antibodies announced today are the result of functional screenings from the top 300 lead antibodies analyzed from the human and llama campaigns. The Company has stated that functional analysis of the remaining 1,300 lead antibodies from the rabbit and OmniAbÒ rat campaigns were performed independently, and they anticipate the release of the preliminary functional data screens from these additional programs in the near future.

"Arriving at this critical point in our preliminary research with many lead, functional therapeutic candidates is indicative of the broad scientific scope of IPA's anti-COVID-19 programs," stated Dr. Jennifer Bath, CEO and President of IPA. "An effective cocktail therapy for COVID-19, targeting multiple epitopes on the virus, could prove fundamental in combating this pandemic in an effective and enduring way."

The Company's scientific approach has led to a diverse set of lead antibody candidates, and thus far has generated many potently neutralizing antibodies to multiple epitopes, supporting the Company's aim of generating a therapeutic that retains efficacy, even as SARS-CoV-2 continues to evolve. To further support the Company's robust scientific approach, IPA is preparing to test these lead antibodies against additional, documented, mutated strains of the virus.

The Company anticipates pre-clinical studies will begin summer 2020.

Jennifer Bath, Ph.D., Chief Executive Officer of ImmunoPrecise, has reviewed and approved the scientific disclosure of this news release.

The use of therapeutics for humans in clinical trials will require approval of the applicable government regulation agency, e.g. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain COVID-19 (or SARS-CoV-2) at this time.

About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a full-service, therapeutic antibody discovery Contract Research Organization offering species agnostic, multi-format, characterized and engineered, human monoclonal antibodies, on an abbreviated timeframe, for its pharmaceutical clients. For further information, visit www.immunoprecise.com or contact [e-mail].

Forward Looking Information
This news release contains statements that, to the extent they are not recitations of historical fact, may constitute "forward-looking statements" within the meaning of applicable Canadian securities laws. The Company uses words such as "may", "would", "could", "will", "likely", "expect", "believe", "intend" and similar expressions to identify forward-looking statements. Any such forward-looking statements are based on assumptions and analyses made by ImmunoPrecise in light of its experience and its perception of historical trends, current conditions and expected future developments. However, whether actual results and developments will conform to ImmunoPrecise's expectations and predictions is subject to any number of risks, assumptions and uncertainties. Many factors could cause ImmunoPrecise's actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things, ImmunoPrecise may not be successful in the development of any vaccine, therapy or diagnostic kits to be used in the prevention, treatment or diagnosis of SARS-CoV-2, actual revenues and earnings for IPA being lower than anticipated, potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and clinical trials, supply chain interruptions and disruption of the global economy, and those risks and uncertainties described in ImmunoPrecise's annual management discussion and analysis for the previous quarter ended January 31, 2020 which can be accessed at www.sedar.com. The "forward-looking statements" contained herein speak only as of the date of this press release and, unless required by applicable law, ImmunoPrecise undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE ImmunoPrecise Antibodies

[Py11]

News out!

[Py11]

Exciting stuff! Should be lots of news the next month. Antibody characteristics and then hopefully followed by some big licensing deals.

[mikeonmicrocaps]

Hmmm

Takeover??

[CTaylor0408]

halted pending news ....

[Simbeez]

You have it right. Hearing it is very close to release. I hope they take into consideration the holiday period. I think people will be pleased with what they find. They should be on Nasdaq, I think in the very near future. Which to me means they will meet the valuation requirements. I am sure institutional investors will be clamoring to get a piece of the action which will only push the valuation even higher. They are probably already talking to these institutional investor groups already since their goal for the year is to get on Q exchange and will need them for a financing in the US.

Hang in there. We are very close. Good luck.

[Py11]

Ya I was thinking it could take longer than we think. $VIR announced a collaboration with NIH in March for antibody characteristics and they announced their results mid May. I don’t think it will take another month with IPA but maybe another week or two. Hoping for some great results followed by 1 or more big licensing deals. Tons of money going into Covid treatment companies so IPA could see some explosive movement soon.

[Simbeez]

Hello, Py
Sorry have not been around. Yes, that's what I have been hearing around here in the True North and strong....land of snow (lot's of it too). The data should be out soon, I am thinking before end of net week. The only thing is they may want to delay it by a week to get through Canada Day July 1 and July 4th holidays. The functional data is what this a very exciting play. The dips were nice for some to pick up. Cormack (brokerage) was buying up everything or most of the shares this past week. Everyone, waiting for the data anxiously. I think the data will be good since they already have a couple of collaboration types of agreements already. Connected to major Pharma with IPA will see great upside. Hold tight!!!

[Py11]

Back up we go. Should be seeing functional data any day now. I believe that’s when the fun will start.

[Py11]

Collaborative COVID-19 Vaccine Project Between ImmunoPrecise Antibodies Europe and LiteVax BV, Funded Through TRANSVAC2

https://www.newswire.ca/news-releases/collaborative-covid-19-vaccine-project-between-immunoprecise-antibodies-europe-and-litevax-bv-funded-through-transvac2-838918671.html

[Py11]

Exciting times ahead here. After they release peer reviewed antibody data and maybe a partnership we should see IPATF over $4.00. They can then think about uplisting to NASDAQ which would be huge for investors.

[shurtha2000]

watching and keeping quiet

[Py11]

https://worldstrend.com/therapeutic-market-will-generate-massive-revenue-in-future-a-comprehensive-study-on-key-players-novartis-astrazeneca-cipla-abbvie/

[Simbeez]

I agree. Immunoprecise mentioned in the following article with all the big boys!!!


https://3wnews.org/uncategorised/1227777/latest-news-2020-global-covid-19-therapeutic-market-by-coronavirus-covid19-impact-analysis-with-top-manufacturers-analysis-top-players-cadila-healthcare-johnson-johnson-immunoprecise-nova/

[Py11]

If they partner up with JNJ or some other big pharma then this will go way passed $4.00. Especially in this crazy market right now. One step at a time though. Release the antibody data to the public and then hopefully partner up with someone to develop a antibody cocktail.

[shurtha2000]

Needs to go to NASDAQ soon GLTA cya later

[Simbeez]

Damn, you sniffed out our secret, Shurth. Py we got company. Nice to have you on board. You will be very happy. Hope you got a pile of this in your kitty. This is an easy $4 US, but I think it will be much more than that. Only around 70 Million float including around 23% owned by insiders. Good Luck.

[shurtha2000]

Next stop $2

[shurtha2000]

Multi day runner here

[shurtha2000]

OMG no one knows about this stock just the two of you

[Simbeez]

Hi Py,
Yes, I hear lot's of GOOD news flow is comming very soon. Keep your seat belt on!!!

[Py11]

They should be releasing a peer reviewed article soon on their neutralizing antibodies. I’m sure they’ll soon partner up with big pharma. Could end up being Janssen due to their previously announced agreement. Exciting times ahead.

[Simbeez]

Yes, it was the same up north too. I picked up another 10 K shares. News is out.

ImmunoPrecise Collaborates with the NIH and Integrated Biotherapeutics to Study the Structural Details of Antibodies with Therapeutic Potential to Treat or Prevent Coronavirus Disease 2019 (COVID-19)

VICTORIA, BC, June 4, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV: IPA) (OTCQB: IPATF), a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, today announced it is collaborating, pursuant to an agreement dated May 14, 2020, in a multi-company effort with the laboratory of Dr. Frederick Dyda at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health (NIH), and Dr. M. Javad Aman at Integrated Biotherapeutics (IBT), to better understand the molecular binding interactions of potential therapeutic antibody candidates resulting from IPA's SARS-CoV-2 programs aimed at treating or preventing COVID-19.



This research consortium unites three reputable teams for lead antibody characterization, using Cryogenic Electron Microscopy (Cryo-EM) to determine the structural details of antibodies bound to the spike protein from the SARS-CoV-2 virus. IBT will provide the well-characterized trimeric spike protein ectodomain and the receptor binding domain (RBD) against which IPA's antibodies will be characterized using Cryo-EM performed in Dr. Dyda's laboratory.

Cryo-EM is a microscopy technique that uses an electron beam as its primary energy source (instead of a light beam), which allows for much greater resolution and magnification than with a traditional microscope and is emerging as a mainstream technique in structural biology. An initial cooling of the sample to cryogenic temperatures enables determination of the macromolecular structures under analysis, in this case, the atomic resolution that can be used to elucidate the precise epitopes targeted by IPA's antibodies in their molecular binding interactions with the SARS-CoV-2 spike protein. The data will shed light on the Company's understanding of how their lead candidate antibodies neutralize the virus that is causing COVID-19.

"The tripartite collaboration will deliver detailed, molecular-level understanding of how our lead antibodies interact with and neutralize the pathogenic SARS-CoV-2 spike protein", stated Yasmina Abdiche, CSO of ImmunoPrecise. "This information is critical in elucidating their mechanism of action and informing their combination into therapeutic cocktails that aim to provide potent and long-lasting protection against COVID-19 and emerging virus variants."

"We welcome this synergistic collaboration with ImmunoPrecise and the NIH towards delineation of critical sites of vulnerability in the SARS-CoV-2 that can lead to development of safe and effective immunotherapies for COVID-19", added M. Javad Aman, President and CSO of IBT.

[Py11]

Strong volume here today on the US side. Nice to see more US investors making the IPA discovery. This company is still a secret and will be worth a whole lot more once antibody news and partnerships come out.

[Py11]

https://edge.investments/make-cash-in-the-crash-with-a-pandemic-portfolio/

[Py11]

Let’s see some antibody data next week!

[Py11]

https://www.uvic.ca/news/topics/2020+brolo-covid-home-test+news

[Py11]

https://equity.guru/2020/05/27/biotech-will-survive-covid-19-hype-ends/amp/

[Py11]

Would love to know more about how the technology works. Using your phone camera to detect Covid antibodies in your saliva would obviously be extremely valuable. Getting data immediately would allow governments to manage the virus better.

[Simbeez]

It's a great piece of news. Totally a game changer. Could be licensed all over the world....WOW. Just think of the revenues that could flow from this. Apparently, this technology was successful with the Zika virus as noted in the NR. Just adds to the market cap to the company. I can only imagine what the next piece of news would be and where that would take us to. Sky's the limit. I am glad there are two rocket ships going up today - Space X and IPA...lol

[Py11]

Didn’t expect test kit news! A test that’s done with a phone and saliva would be a game changer in managing the virus. No idea how the technology works and how accurate it is but could be very valuable. They also said this is just one portion of their coronavirus program. This is a good start!

[Simbeez]

NSERC Awards Grant to Fund Collaboration Between ImmunoPrecise and the University of Victoria for the Generation of a Potential COVID-19 Antibody-Based Test in Canada that can Provide Real-Time Responses

VICTORIA, May 27, 2020 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB: IPATF), specialists in custom antibody discovery and development, today announced a collaboration between University of Victoria ("UVic")-based laboratory of Dr. Alexandre Brolo, experts in the development of novel diagnostic tools, and ImmunoPrecise Antibodies. The objective of this partnership is to develop a colorimetric antibody-based test for the detection and screening of COVID-19. Although most immunoassays are developed for blood or serum, this team is aiming to use patient saliva. The goal is to enable the test to be realized with an easily obtainable sample, which should be suitable for a home-test kit. The color change readout will be measured using a cell phone camera and analyzed by a custom cell phone application. The results, including the general location (by zone rather than by specific household, to comply with privacy rights) of the test, can be uploaded to a cloud-hosted database. This will provide immediate information about the number of infections and the general locations to the health authorities. The program builds on successful technology previously developed by Dr. Brolo's laboratory for the detection of the Zika virus. This previous technology demonstrated positive results in a pilot field study performed in Brazil, which verified the technology's ability to detect Dengue/Zika proteins using patient saliva samples.

"While the diagnostic testing is only one portion of IPA's overall Coronavirus program, the need for a highly reliable, quick and easy to administer diagnostic is an unmet need, and the laboratory of Dr. Brolo has the expertise and game plan we are honored to contribute to", stated Dr. Jennifer Bath, President and CEO of IPA.

Monoclonal, highly specific antibodies are the main component required for the development of immunoassays. The antibodies for this project will be generated using IPA's unique proprietary B cell Select™ platform. The high affinity and selectivity of the resulting antibodies will enable tests with no-cross-reactivity, low background, and enhanced detection. IPA and Dr. Brolo's group will work together to establish the most appropriate targets for the COVID-19 detection and to secure patient samples for validating the tests.

"We are interested in partnering with the Brolo group to speed up the application of these antibodies in a colorimetric antibody-based test for the detection and screening of COVID-19", explains Dr. Barry Duplantis, Canada project lead for diagnostics. "We have the expertise and networks to support the commercialization of the detection technology that incorporates our monoclonal antibodies".

The one-year NSERC award consists of a $50,000 grant to the Brolo laboratory. ImmunoPrecise will provide the antibodies to be used in the kit and will retain an exclusive option on the commercialization rights. Reasonable commercial terms will enable IPA to efficiently bring the technology to market and reach those in need quickly. All agreements will align with NSERC and UVic intellectual property and research policies and ensure utilization of results of this research for the benefit of Canada and Canadians, with the submission of research results in open access, peer-reviewed literature.

IPA and UVic are already working within their respective roles on the COVID-19 diagnostic platform. IPA is actively engaged in the process of screening antibody panels already under development, to determine which antibodies best meet the profile for those required in the diagnostic kit. The antibodies will then be tested against SARS-CoV-2 spike protein and validated using both convalescent and naïve, human patient samples. Validation of the portable diagnostic will then require approval by Health Canada prior to field tests and / or commercialization.

Additional Debenture Issuance

The Company also announces that further to its non-brokered private placement (see news release dated May 15, 2020) it has issued an additional CAD $35,000 of 10% convertible debentures. In total, the Company issued CAD $2,627,000 of convertible debentures on the financing.

The debentures issued under this tranche are unsecured, bear interest at a rate of ten percent (10%) per year, payable annually, and are due May 22, 2022 (which may be repaid early at the option of the Company). The principal amount of the debentures may be convertible, at the option of the holder, into shares of the Company at a conversion price of CAD $0.85 per share. The Company may force convert the principal amount of the debentures at CAD$0.85 per share if the average closing price is equal to or greater than CAD $1.50 for 20 trading days. In order to exercise this right, the Company must issue a news release announcing its intention to exercise this right within 10 business days after the end of the particular 20-day period.

The securities under this tranche are subject to restrictions on resale expiring on September 16, 2020. The Company paid a finder's fee totaling $1,750 under this final tranche.

About Brolo Group

Dr. Alexandre G. Brolo is a professor at the University of Victoria in Canada where he directs an innovative, multidisciplinary, and high-impact research program that spans the areas of nanotechnology, surface spectroscopy, electrochemistry and bioanalytical chemistry. Dr. Brolo's research is centered on the optical and spectroscopic properties of metallic nanostructures that support a physical phenomenon called "surface plasmon excitation". His work explores the fabrication, characterization, and application of these metallic nanostructures in biosensing and in enhanced spectroscopy, particularly in their use for remote chemical sensing and in combination with microfluidics. Dr. Brolo has published more than 150 research papers in top international journals and conference proceedings and presented on numerous occasions.

About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise is a full-service, antibody discovery Contract Research Organization offering species agnostic, multi-format, characterized and engineered, human monoclonal antibodies, on an abbreviated timeframe. For further information, visit www.immunoprecise.com or contact [e-mail]. There is no assurance that ImmunoPrecise will be successful in the development of a diagnostic for the new Coronavirus.

Forward Looking Information

This news release contains statements that, to the extent they are not recitations of historical fact, may constitute "forward-looking statements" within the meaning of applicable Canadian securities laws. The Company uses words such as "may", "would", "could", "will", "likely", "expect", "believe", "intend" and similar expressions to identify forward-looking statements. Any such forward-looking statements are based on assumptions and analyses made by ImmunoPrecise in light of its experience and its perception of historical trends, current conditions and expected future developments. However, whether actual results and developments will conform to ImmunoPrecise's expectations and predictions is subject to any number of risks, assumptions and uncertainties. Many factors could cause ImmunoPrecise's actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things, actual revenues and earnings for IPA being lower than anticipated, and those risks and uncertainties described in ImmunoPrecise's annual management discussion and analysis for the last quarter of the fiscal year ended January 31, 2020 which can be accessed at www.sedar.com. The "forward-looking statements" contained herein speak only as of the date of this press release and, unless required by applicable law, ImmunoPrecise undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE ImmunoPrecise Antibodies

SOURCE ImmunoPrecise Antibodies Ltd.

https://www.prnewswire.com/news-releases/nserc-awards-grant-to-fund-collaboration-between-immunoprecise-and-the-university-of-victoria-for-the-generation-of-a-potential-covid-19-antibody-based-test-in-canada-that-can-provide-real-time-responses-301065701.html

[Py11]

Talem Therapeutics, has entered into a research license agreement (the "Agreement") with Janssen Research & Development, LLC ("Janssen"), providing Janssen exclusive access to a panel of novel, monoclonal antibodies against an undisclosed target. Pursuant to the Agreement, Janssen holds an option to acquire all commercial rights to the antibodies.

[Py11]

Yes it would be a great partnership and would also show everyone that IPA is the real deal and on their way to becoming a billion dollar biotech.

[Simbeez]

From Apr 30 NR Johnson & Johnson:

Expanded Antiviral Research
In addition to the vaccine development efforts, BARDA and Johnson & Johnson have also expanded their partnership to accelerate Janssen’s ongoing work in screening compound libraries, including compounds from other pharmaceutical companies.

https://www.jnj.com/johnson-johnson-announces-a-lead-vaccine-candidate-for-covid-19-landmark-new-partnership-with-u-s-department-of-health-human-services-and-commitment-to-supply-one-billion-vaccines-worldwide-for-emergency-pandemic-use


Just 2 weeks after (Apr 14th) this J&J news release IPA announces the Janssens agreement. Reading in between the lines my gut feeling it will be Jannsens as partners. The good thing is that J&J is an american company and has received billions from the US Government. This would be a great partnership for IPA.

[Py11]

Liking where this is right now. Let’s get some positive antibody data and Big Pharma will be knocking at their door.

[Py11]

Other biotechs involved in antibody treatment have had market caps increase by US$1 Billion with positive news. Sounds like it would be too good to be true for ImmunoPrecise to be worth that much but if they have a strong Covid mAb library, why not?

[Simbeez]

I really don't have any definitive answer but I'm hearing from some other investors that it is pretty imminent. It should not have taken them a lot of time to achieve what they are doing, given the massive mAB library they have and the use of AI to isolate the neutralizing anti bodies.

I am sure they are doing their due diligence before releasing the results rather than give prelim data and fail like Moderna and Sorrento. Hopefully, this keeps going up and when they release the research data we will be in the $ Billion market cap range.

[Py11]

You have an idea where they are in terms of research? They’ve been focusing on Covid for months now. They must be very close to announcing details about their discoveries. Hoping that partnership with Janssen leads to a large deal too.

[Simbeez]

I have to agree with you on lack of shares available. Will be a clear case of supply and demand. 1. Price will go through the roof. 2. Large financing deal with one of the institutions. A couple of houses that IPA had deals with previously got into the buying big time in the past weeks, namely Haywood Securities and Cormack. These houses have an insight into IPA as they did the deals before and if they are buying then that's another good sign of things to come. Also, the last major financing in 2018 has 9.1 Million warrants that expire in Sept. 2020, priced at $1.25. This alone will bring over $11 Million into the company's coffers. We have almost reached that threshold for conversions to start happening. As well, there are other previous financing's which have more warrants still o/s. You could see them here if not already done so:
https://tmxmatrix.com/company/IPA/financings

I am really looking forward to the next few weeks / months. Thanks for the article you shared. IPA has the know how and combined with AI it just makes them that much better. As well combination of the all the animal mAB Therapeutics just speeds up the game that much faster.

I am an optimistic, believe in IPA. This is their time to come to the plate and hit the home run.

[Py11]

https://www.wired.com/story/coronavirus-covid-19-antibody-treatment/?utm_source=twitter&utm_medium=social&utm_campaign=onsite-share&utm_brand=wired&utm_social-type=earned

[Py11]

I’m trying to wrap my head around the future valuation of the company if they announce a vaccine or antibody treatment deal with someone like J&J. This Covid-19 is such a global problem that any effective treatment will add a billion dollars to a company’s market cap. If they announce something significant institutions will start buying big and it doesn’t seem like there are many shares available.

[Simbeez]

The share price is still very reasonable for someone to get into IPA, given the potential but window of opportunity is narrowing day by day. I am glad I was able to get into this company long time ago (2+ years). This COVID is obviously none of us dreamt about, who would have thought we would be in the middle of this pandemic. I was just happy with what they were doing as a CRO working with 60 percent of the 20 largest Pharma's. As tragic this is for people dying or suffering from the virus I am really happy that we are in the right sector at the right time. In a way it is good to know that this company has the potential to find the therapeutic cure. I believe there partnership with Janssens will hook them with J&J. J&J has significant funding coming from the US Government for the COVID vaccine. IPA will have everything researched and will just have to pass on the results to J&J for clinical trials and vaccine production.

[Py11]

Ya from my research it looked like they were in a great spot before Covid 19. Now with this virus and being an antibody company I believe this will make them into a very valuable biotech. All depending on what they release and who they partner up with but I wouldn’t be surprised if the market cap goes past 500+ million sometime in the near future. A lot of eyeballs and money going through covid biotechs right now.

[Simbeez]

Yeah, It sure like that way. Something is definitely up. Get ready for the ride. This company is way under valued. I think it is because it is listed on the Canadian side and only on the OTC on the US side. Eventually, it needs to be listed on the big board down south.

Good luck.

Sim